title: Lumbar interbody fusion with utilization of recombinant human bone morphogenetic protein: a retrospective real-life study about 277 patients.
abstract: The purpose of this study was to report an independent real-life experience about the use of recombinant human bone morphogenetic protein 2 in lumbar interbody fusion with a special focus on complications. This is a retrospective single-center cohort study between 2007 and 2013 including 277 patients treated for anterior or posterior lumbar fusion with recombinant human bone morphogenetic protein 2. We report the complications occurring during the 12 first postoperative months and analyze the fusion rate on X-rays. There are 58 cases (22.8%) of clinical complications. In 15 cases (5.9%), these complications were related to the use of recombinant human bone morphogenetic protein 2. Only one patient (0.4%) required a new intervention due to recombinant human bone morphogenetic protein 2. Fusion rate at 1 year was 98%. The low rate of specific complication suggests that recombinant human bone morphogenetic protein 2 can be safe and effective in anterior and posterior interbody fusion when used with simple precautions.
authors.affiliation: Spine Surgery Unit, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur 2, 06000, Nice, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Litrico
authors.affiliation: Spine Surgery Unit, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur 2, 06000, Nice, France. tristanlanglais@yahoo.fr.
authors.forename: Tristan
authors.initials: T
authors.lastname: Langlais
authors.affiliation: Spine Surgery Unit, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur 2, 06000, Nice, France.
authors.forename: Florent
authors.initials: F
authors.lastname: Pennes
authors.affiliation: Spine Surgery Unit, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur 2, 06000, Nice, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Gennari
authors.affiliation: Spine Surgery Unit, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur 2, 06000, Nice, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Paquis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000175:diagnosis / Q000453:epidemiology*; D011859:Radiography; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D013122:Spinal Diseases / Q000000981:diagnostic imaging / Q000601:surgery*; D013123:Spinal Fusion / Q000009:adverse effects* / Q000379:methods; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
chemical_list: D055396:Bone Morphogenetic Protein 2; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2
keywords: Complications; Heterotopic ossification; Lumbar interbody fusion; Radiculitis; Recombinant human bone morphogenetic protein; Retrospective cohort